Vericel: $4 Billion Market Potential for Cartilage Therapy – Record Biopsies Promise New Growth Surge!
Reading Time: 3 minutes
MACI treats cartilage damage with autologous cells and taps into a US market of over $4 billion. The less invasive surgery method MACI Arthro is gaining significance. Record biopsies promise further growth. With 26% revenue growth and 179% profit increase, the UK and ankle joint present new opportunities. MACI – Autologous cartilage cells as a billion-dollar opportunity Vericel offers cell therapies for sports medicine and burns. The key product MACI treats cartilage injuries in the knee. Doctors first take a cartilage sample. Vericel...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
